塞尔帕替尼治疗男性甲状腺髓样癌患者下丘脑-垂体-性腺轴受损
本研究评估19例接受塞尔帕替尼治疗的晚期甲状腺髓样癌男性患者的下丘脑-垂体-性腺轴功能。治疗12个月内FSH显著升高(p=0.03),延伸观察组还出现LH和SHBG升高、总睾酮和游离睾酮下降。勃起功能障碍发生率高达94.7%,中位发生时间1个月,提示塞尔帕替尼可导致性腺功能减退。
要点
- 塞尔帕替尼治疗男性MTC患者勃起功能障碍发生率高(94.7%),中位1个月出现。
- 治疗第一年FSH显著升高,延伸观察组LH、SHBG升高而总睾酮和游离睾酮下降。
- 建议育龄男性起始塞尔帕替尼前评估HPG轴并给予生育咨询。
核心结论
- 塞尔帕替尼治疗的男性MTC患者勃起功能障碍高发且早发,HPG轴受损和精液分析异常提示支持细胞和间质细胞损伤,导致性腺功能减退。
研究设计与样本
- 研究纳入19例接受塞尔帕替尼治疗的晚期甲状腺髓样癌男性患者,检测FSH、LH、总睾酮和SHBG并估算游离睾酮。
- 全部患者(T组)在塞尔帕替尼起始前和12个月后评估HPG轴,其中7例(36.8%)延伸观察超过24个月(Ex组)。
- 6例(31.6%)患者进行了精液分析。
主要发现
- 18/19(94.7%)患者发生勃起功能障碍,其中2例(11.1%)治疗前已有,16例(88.9%)在起始塞尔帕替尼后发生,中位发生时间1个月。
- T组治疗第一年FSH显著升高(p=0.03,+61.9%)。
- Ex组FSH升高(+60.6%)、LH升高(+20.5%)(p<0.01)、SHBG升高(+27.7%)(p=0.04),总睾酮下降(-20%)(p=0.01),游离睾酮下降(-12.5%)(p<0.01)。
- 精液分析显示5例无精子症,1例严重少精子症。
临床怎么用
- 对接受塞尔帕替尼治疗的男性MTC患者,尤其育龄男性,建议起始治疗前评估HPG轴并进行生育咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Erectile dysfunction (ED) is observed during treatment with the highly selective RET inhibitor selpercatinib. A pathogenic hypothesis is the impairment in the hypothalamic-pituitary-gonadal (HPG) axis. This study aims to analyze variations in the HPG axis in male patients with advanced medullary thyroid carcinoma (MTC) treated with selpercatinib. METHODS: 19 male patients were evaluated for FSH, LH, Total Testosterone (TT), and Sex Hormone Binding Globulin (SHBG). Free Testosterone (FreeT) was estimated. In all patients (total group - T-Group), the HPG axis was evaluated before and after 12 months of selpercatinib initiation. In 7/19 (36.8%) cases (extended group - Ex-Group), data collection was extended beyond 24 months from the start of treatment. Semen analysis was performed in 6 (31.6%) patients. RESULTS: 18/19 (94.7%) patients experienced ED: 2 (11.1%) had ED before, while 16 (88.9%) developed ED after starting selpercatinib. The median time to ED onset was 1 month. During the first year of treatment, a significant increase in FSH (p = 0.03) (+61.9%) was observed in the T-Group. In the Ex-Group, a significant increase in FSH (+60.6%), LH (+20.5%) (p < 0.01), and SHBG (+27.7%) (p = 0.04), and a decrease in TT (-20%) (p = 0.01) and FreeT (-12.5%) (p < 0.01) were observed. Five patients had azoospermia, and one severe oligospermia. CONCLUSIONS: ED shows high prevalence and early onset in males with MTC treated with selpercatinib. Impairment in the HPG axis and semen analysis can reflect damage to Sertoli and Leydig cells, leading to hypogonadism. Therefore, HPG axis evaluation and fertility counseling could be advisable mainly in childbearing males before starting selpercatinib.
引用
- Matrone A, Gambale C, Prete A, et al. Impairment in the hypothalamic-pituitary-gonadal axis in males with medullary thyroid carcinoma treated with selpercatinib. J Clin Endocrinol Metab. 2026. PMID: 42489134. doi:10.1210/clinem/dgag296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。